SecBot SecBot

PYPD

PolyPid Ltd.
Nasdaq· Surgical & Medical Instruments & Apparatus· Inc. L3· CIK 0001611842 Healthcare & Medical Devices
$5.29 +0.04 (+0.76%)
Oct 26 4:00 PM ET · prev $5.25
Market cap
$104.2M
Micro cap
Median target
$12.50
+136% · range $8.00–14.00
Next earnings
Nov 11
in 16 days · EPS est. $0.27
1 year
+46.5%
from $3.61 · Oct 27
30 days
−0.4%
from $5.31
52-week range
$3.58–5.58
−5% from high · low Nov 13
Avg volume 20D
106.8K
shares / day
Short interest
🔒 Subscribers only
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
14
analyzed by SecBot
SecBot read BULLISH 9 reports · 90 days
Balance 0 bearish · 7 bullish · 1 mixed · 1 neutral oldest → newest, height = score
Avg score ·High conf. 8/9 ·Next Earnings date, Nov 11, 2026
Strongest BULLISH PolyPid announced that the European Medicines Agency (EMA) validated its Marketing Authorization Application…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsMIXED

    Q2 2026: 2 added (0 new), 3 trimmed or exited.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.315 → $0.270 over 90 days. 1 up, 0 down in 30 days.

  • TrendRANGE

    3% above its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
MORGAN STANLEYTRIM123,136$625.5K
RENAISSANCE TECHNOLOGIES LLCDOUBLED116,619$592.4K
JANE STREET GROUP, LLCDOUBLED83,126$422.3K
CITADEL ADVISORS LLCTRIM42,282$214.8K
BNP PARIBAS FINANCIAL MARKETSTRIM3,004$15.3K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Jul 2026
12-month targets · 4 analysts

Price is below the lowest target. Median implies +136%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Jul 21, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 11, 2026
Earnings date
PYPD Q3 2026 Earnings Scheduled — 2026-11-11
Recent
Oct 15, 2026
Announcement
PolyPid to Host Virtual Investor Day on Wednesday, October 28, 2026
Management to outline ‘PolyPid 2030’, the Company’s long-term vision and pipeline strategy Event to feature Warren S. Joseph, DPM, FIDSA, a…
Oct 1, 2026
Announcement
European Medicines Agency Validates PolyPid’s Marketing Authorization Application for D-PLEX₁₀₀
PolyPid Submitted Marketing Authorization Application to European Medicines Agency for D-PLEX₁₀₀ Last month
Oct 1, 2026
Announcement
PolyPid Regains European Commercialization Rights for D-PLEX₁₀₀, Expanding Global Commercialization Opportunities
PETACH TIKVA, Israel, Oct. 01, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical…
Aug 12, 2026
Earnings
PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results
FDA Accepted D-PLEX₁₀₀ NDA with Priority Review; PDUFA Goal Date of November 28, 2026, Approximately One Quarter Ahead of Previously Communicated…
Aug 12, 2026
Earnings date
PYPD Q2 2026 Earnings Scheduled — 2026-08-12

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Jul 15, 2026
Krinsky Itzhak
Director
AWARD$40.7K
Jul 15, 2026
Akselbrad Dikla Czaczkes
Chief Executive Officer
AWARD$664.5K
Jul 15, 2026
Barenholz Yechezkel
Director
AWARD$40.7K
Jul 15, 2026
Story Brooke
Director
AWARD$40.7K
Jul 15, 2026
Dror-Darwish Nir
Director
AWARD$40.7K
Jul 15, 2026
Stein Robert Benjamin
Director
AWARD$40.7K
Jul 15, 2026
BenAmram Joseph
Director
AWARD$40.7K
May 11, 2026
Warshavsky Ori
Chief Operating Officer - US
AWARD$205.2K

Earnings setup

Estimates
Nov 11
reports in 16 days
$0.27
EPS estimate, this quarter
+186%
estimate change, 90 days
1↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q$0.27-$0.41–$0.96+0.0%$15.0M
Next Q-$0.41-$0.56–-$0.29+0.0%$0.00
Current FY-$0.89-$1.68–-$0.04+0.0%$15.0M
Next FY-$1.23-$1.97–-$0.70+0.0%$8.7M

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 15, 2026 Press
PolyPid announced a virtual Investor Day on October 28, 2026, to unveil its 'PolyPid 2030' long-term strategy and…
Impact 3/10
Oct 15, 2026 Announcement
PolyPid to Host Virtual Investor Day on Wednesday, October 28, 2026
Management to outline ‘PolyPid 2030’, the Company’s long-term vision and pipeline strategy Event to
Oct 1, 2026 SEC
PolyPid announced that the European Medicines Agency (EMA) validated its Marketing Authorization Application (MAA) for…
6-K — Impact 7/10
Oct 1, 2026 Press
PolyPid announced that the EMA has validated its MAA for D-PLEX100, initiating formal regulatory review for EU…
Impact 7/10
Oct 1, 2026 SEC
PolyPid regained exclusive European commercialization rights for D-PLEX after mutually terminating its 2022 license…
6-K — Impact 6/10
Aug 12, 2026 SEC
PolyPid reported H1 2026 results showing a net loss of $15.6M (improved from $18.2M in H1 2025) with cash of $6.6M and…
6-K — Impact 7/10
Jul 15, 2026 Insider
Krinsky Itzhak was granted 9,132 shares
Director @ $4.46 ($40.7K)
Jul 15, 2026 Insider
Akselbrad Dikla Czaczkes was granted 149,000 shares
Chief Executive Officer @ $4.46 ($664.5K)

SecBot reports

14 filings · 7 press releases · 11 bullish · 0 bearish · 3 neutral
All PYPD filing & press-release reports (21)